Ascletis Pharma (Ascletis, 1672.HK) and Suzhou Alphamab jointly announce that Ascletis' subsidiary and Alphamab have entered into a strategic collaboration and exclusive licensing agreement for anti-PD-L1 KN035 to treat hepatitis B and other viral diseases in Greater China (Ascletis code: ASC22).
Charles River Laboratories International has collaborated with Atomwise on integrated and artificial intelligence (AI)-driven drug discovery.
Selexis has expanded its alliance with clinical-stage immuno-oncology company Agenus by signing additional commercial license agreements (CLAs).
Elevian and Insilico Medicine have announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets.
CANbridge Pharmaceuticals and WuXi Biologics have expanded their rare disease therapeutics partnership to enable the former to discover, develop and commercialize four additional drug candidates.
Pfizer has signed a collaboration agreement to use CytoReason’s machine learning model of the immune system for drug discovery.
Gilead Sciences has signed a licensing and collaboration agreement, potentially worth $785m, with South Korea-based Yuhan to develop new therapeutic candidates for the treatment of advanced fibrosis due to nonalcoholic steatohepatitis (NASH).
Adaptive Biotechnologies has entered into a worldwide collaboration and license agreement with Roche Group’s Genentech to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a range of cancers.
French multinational pharmaceutical company Sanofi investing €80m in equity in BioNTech, which is claimed to be the Europe’s largest privately-held biopharmaceutical firm focused on the development of individualized therapies for cancer and the prevention of infectious diseases.
Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target emerging from its research collaboration and license agreement with Dicerna.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.